Research programme: neuropsychotherapeutics - EpiVario
Alternative Names: epigenetic regulators modulatorsLatest Information Update: 28 Jan 2023
At a glance
- Originator University of Pennsylvania
- Developer EpiVario
- Class Antidementias; Anxiolytics; Drug withdrawal therapies; Small molecules
- Mechanism of Action Acetate-CoA ligase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alcoholism; Alzheimer's disease; Post-traumatic stress disorders; Substance-related disorders
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Alcoholism in USA
- 28 Jan 2023 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 28 Jan 2023 No recent reports of development identified for preclinical development in Post-traumatic-stress-disorders in USA